EUVIMEDEUVIMED entdecken
Open Access

Using protein turnover assay to explore the drug mechanism of Carfilzomib

Yonghui Tao, Xinyu Ding, Caiwei Jia, Chengcheng Wang, Chuanyin Li

Acta Biochimica et Biophysica Sinica · 2025

DOI: 10.3724/abbs.2024104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biochimica et Biophysica Sinica, 2025. Verfasst von Yonghui Tao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Labora…. Hauptthemen laut MEDLINE: Oligopeptides, Multiple Myeloma, Proteasome Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carfilzomib (CFZ) is the second-generation proteasome inhibitor that is approved by Food and Drug Administration (FDA) of USA for the treatment of relapsed and refractory multiple myeloma. Although the preclinical and clinical efficacy of CFZ is obvious, the mechanism by which CFZ leads to cell death has not been fully elucidated. Since CFZ primarily functions as a proteasome inhibitor, profiling CFZ-induced changes in protein turnover at the systematic level is sufficient and necessary. In this study, we characterize the effects of CFZ on the stability of 15,000 human proteins using Protein Turnover Assay (ProTA). CFZ affects fundamental cellular glycolysis, nitric oxide production and proteasome subunit homeostasis in multiple myeloma cells. In addition, LY294002 or KU-0063794 has synergistic effects with CFZ in multiple myeloma treatment. A profound understanding of how cells respond to chemotherapeutic agents provides insights into the basic mechanism of drug function and the rationale for CFZ combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligopeptidesMultiple MyelomaProteasome InhibitorsAntineoplastic AgentsHumansCell Line, TumorProteasome Endopeptidase ComplexGlycolysisDrug SynergismNitric OxideProtein Stability

Stichwörter der Autor:innen

Carfilzomibmultiple myelomaprofilingprotein homeostasis

Substanzen

carfilzomibOligopeptidesProteasome InhibitorsProteasome Endopeptidase ComplexAntineoplastic AgentsNitric Oxide

Autor:innen und Institutionen

  • Department of Colorectal Surgery and Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences, Zhejiang Province, Chin…
  • State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Sh…
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
  • School of Medicine, Guizhou University, Guiyang 550025, China.

Zitieren

APA

Tao, Y., Ding, X., Jia, C., Wang, C., & Li, C. (2025). Using protein turnover assay to explore the drug mechanism of Carfilzomib. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024104

Vancouver

Tao Y, Ding X, Jia C, Wang C, Li C. Using protein turnover assay to explore the drug mechanism of Carfilzomib. Acta Biochimica et Biophysica Sinica. 2025. doi:10.3724/abbs.2024104

BibTeX
@article{Tao2025,
  author = {Tao, Yonghui and Ding, Xinyu and Jia, Caiwei and Wang, Chengcheng and Li, Chuanyin},
  title = {Using protein turnover assay to explore the drug mechanism of Carfilzomib},
  journal = {Acta Biochimica et Biophysica Sinica},
  year = {2025},
  doi = {10.3724/abbs.2024104}
}
Kostenlos starten →